肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展

Research progress of TNF-α and its receptors in rheumatoid arthritis

肿瘤坏死因子α(TNF-α)信号通路是治疗自身免疫性疾病的重要靶点。TNF-α能够结合到2个不同的受体上,通过与受体的结合发挥抗炎、抗风湿的作用。抗TNF-α的药物被广泛应用于类风湿性关节炎(RA)的治疗,如英夫利昔单抗、阿达木单抗等。其在抑制炎症引起的损伤及受损组织的恢复等方面具有重要作用,但是也会引起一定的副作用,如增加感染和恶性肿瘤的风险、引起新的自身免疫性疾病等。这些副作用可能是由于封闭了TNF-α的有益信号引起的,而选择性拮抗肿瘤坏死因子受体(tumor necrosis factor receptor,TNFR)可能是解决TNF-α抗体副作用的一个重要途径,特异性地作用于TNFR的药物具有更加广阔的实用性和安全性。针对TNF-α及其受体的药物在RA中的研究进展进行综述。

The TNF-α signaling pathway is a valuable target in the therapy of autoimmune diseases . TNF-α binds to two different receptors and exerts anti-inflammatory and anti-rheumatic effects . The drugs of anti-TNF-α are widely used in rheu-matoid arthritis , such as infliximab , adalimumab etc . These TNF blockers have become invaluable tools to reduce damages in - duced by inflammation and allow recovery of the affected tissues . Unfortunately , this therapy has some drawbacks , such as in-creasing the risk of infection , malignancy and the incidence rate of new auto-immune diseases . Some of these effects are caused by the unwanted abrogation of beneficial TNF signaling . Therefore, elective antagonism of TNFR is an important approach to alleviate the side effects of TNF-α antibody . The medications specifically targeting the TNFR might have better applicability and safety . In this article,research progresses of TNF-α and its receptors in the therapy of rheumatoid arthritis were reviewed .